UTMD Stock Recent News
UTMD LATEST HEADLINES
SALT LAKE CITY, UT / ACCESSWIRE / August 2, 2024 / Utah Medical Products, Inc. (Nasdaq:UTMD) announces that its Board of Directors approved a quarterly cash dividend of thirty cents ($.30) per share of common stock payable on October 4, 2024 to stockholders of record at the close of business on September 20, 2024. This is a 1.7% increase over the dividend declared in the same quarter of the prior year.
Utah Medical (UTMD) reports a 19.2% revenue decline in 2Q24, with EPS down 15.3% due to lower sales to major customers. Despite this, profit margins remained stable.
SALT LAKE CITY, UT / ACCESSWIRE / July 25, 2024 / As previously projected, Utah Medical Products, Inc. (Nasdaq:UTMD) realized second calendar quarter (2Q) and first half (1H) 2024 financial results which reflect a substantial decline in revenues. Currencies in this release are denoted as $ or USD = U.S. Dollars; AUD = Australia Dollars; £ or GBP = UK Pound Sterling; C$ or CAD = Canadian Dollars; and € or EUR = Euros.
Explore why Zacks rates UTMD with a "Neutral" recommendation, being the first on Wall Street to initiate coverage on the stock. Learn about UTMD's financial stability, diverse product portfolio, and market opportunities, balanced against key challenges in the competitive medical device industry.
Utah Medical Products stock has dropped 14% and is at its lowest point this year due to ongoing lawsuits regarding its Filshie clip system. The lawsuits do pose a risk to UTMD's stock price, and a negative outcome could further impact the company's equity. Despite the risks, UTMD's long-term economics and attractive proposition in multiple markets are bullish features.
Utah Medical Products comes with high returns on capital and projected earnings growth into FY'25. The company has compounded earnings at a rate of 2.8x that of revenue since 2021. Net-net, reiterate buy, eyeing a long-term price target of $223 per share.
Utah Medical Products: Recycling Capital Well, Long-Term Gains On The Table
UTMD is a relatively undercovered, unexploited name that historically trades within a narrow trading range, within a defensive sector. With this in mind, we wanted to see how it fits in within a cross-asset balanced portfolio setup.